AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

American drug major AbbVie Healthcare’s Indian arm, which is under the scanner for sponsoring foreign trips of 30 doctors in violation of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP ...

ABBV-932 is under clinical development by AbbVie and currently in Phase I for Schizophrenia. According to GlobalData, Phase I drugs for Schizophrenia have a 66% phase transition success rate (PTSR) ...

The Apex Committee for Pharma Marketing Practices has found Abbvie Healthcare India Private Ltd in breach of the UCPMP ( Uniform Code for Pharmaceutical Marketing Practices), by sponsoring ...

The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of ...

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to ...

AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

Polaris Global Equity Strategy highlighted stocks like AbbVie Inc. (NYSE:ABBV) in its Q3 2024 investor letter. AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures, and sells pharmaceuticals.

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie ABBV made an insider sell. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on ...

“These harms are more than speculative,” he added. The preliminary injunction means West Virginia is blocked from enforcing S.B. 325 against Novartis and AbbVie while the cases play out. The industry ...

AbbVie, a drug company based in North Chicago, Illinois, is paying $200 million to acquire Madison-based Nimble Therapeutics, which is developing an oral therapy that could treat psoriasis and ...